Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse-Remitting Multiple Sclerosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableActive Not RecruitingNCT05605782
What this trial is testing

A Post-Authorization, Long-term Study of Ozanimod Real-world Safety

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Bristol-Myers Squibb 9,000
Not applicableStudy completedNCT02490982
What this trial is testing

Teriflunomide Observational Effectiveness Study

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Centre hospitalier de l'Université de Montréal (CHUM) 106
Not applicableUnknownNCT05290688
What this trial is testing

Cellular microRNA Signatures in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Institut Pasteur 20
Not applicableEnded earlyNCT02949908
What this trial is testing

MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)

Who this might be right for
Multiple Sclerosis
Merck KGaA, Darmstadt, Germany 2
Post-approval studies (Phase 4)WithdrawnNCT00771043
What this trial is testing

A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Biogen
Not applicableStudy completedNCT02633033
What this trial is testing

Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Mallinckrodt 160
Early research (Phase 1)Active Not RecruitingNCT07597668
What this trial is testing

A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations

Who this might be right for
Multiple Sclerosis
R-Pharm 180
Testing effectiveness (Phase 2)Ended earlyNCT00623415
What this trial is testing

Flupirtine as Oral Treatment in Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Charite University, Berlin, Germany 30
Not applicableStudy completedNCT02652091
What this trial is testing

Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Bayer 146
Not applicableLooking for participantsNCT06276634
What this trial is testing

Intermittent Hypoxia in Persons With Multiple Sclerosis

Who this might be right for
Multiple SclerosisMultiple Sclerosis-Relapsing-RemittingMultiple Sclerosis, Secondary Progressive
Shirley Ryan AbilityLab 21
Not applicableUnknownNCT05735067
What this trial is testing

The Impact of Body Weight on Clinical and Immunological Outcomes in Relapse-Remitting Multiple Sclerosis Patients

Who this might be right for
Multiple Sclerosis
German University in Cairo 138
Not applicableStudy completedNCT03347370
What this trial is testing

A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Biogen 626
Testing effectiveness (Phase 2)Active Not RecruitingNCT04530318
What this trial is testing

Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Judit Pich 45
Not applicableStudy completedNCT04115930
What this trial is testing

Correlation Between Daily Physical Activity and Disability, Fatigue, Cognition and Quality of Life in MS Patients

Who this might be right for
Relapsing Remitting Multiple SclerosisFatigueQuality of Life+1 more
University of Eastern Finland 61
Not applicableLooking for participantsNCT06586177
What this trial is testing

Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Heinrich-Heine University, Duesseldorf 100
Not applicableStudy completedNCT02137707
What this trial is testing

Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya

Who this might be right for
Multiple Sclerosis-Relapsing-Remitting
McGill University 135
Testing effectiveness (Phase 2)Study completedNCT00942591
What this trial is testing

Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b

Who this might be right for
Multiple Sclerosis
Insel Gruppe AG, University Hospital Bern 77
Testing effectiveness (Phase 2)Study completedNCT01051817
What this trial is testing

POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler

Who this might be right for
Relapsing-remitting Multiple SclerosisRRMS
Novartis Pharmaceuticals 73
Not applicableStudy completedNCT01080040
What this trial is testing

To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients

Who this might be right for
Multiple Sclerosis, Relapsing Remitting
Merck KGaA, Darmstadt, Germany 150
Post-approval studies (Phase 4)Study completedNCT03963375
What this trial is testing

Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Gregory Wu 47
Next Page